Communiqués PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,610 ^USD	-9,55%		+18,38%	+28,80%

05/10	Pmv Pharmaceuticals, Inc. annonce la nomination de Matt Eckler à son conseil d’administration	CI
08/09	PMV Pharmaceuticals, Inc. annonce la nomination de Philip Herman au poste de Chief Commercial Officer	CI

Communiqués

05/10	PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors	AQ
08/09	PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer	AQ
01/09	PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities	AQ
31/08	PMV Pharma Announces Proposed Public Offering of Securities	AQ
31/08	PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial	AQ
14/08	PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights	AQ
12/05	PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights	AQ
22/04	PMV Pharmaceuticals Announces Board Chair Transition	AQ
06/03	PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights	AQ
26/02	New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors	AQ
12/11	PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights	AQ
24/10/25	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation	AQ
13/10/25	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	AQ
10/09/25	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation	AQ
07/08/25	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights	AQ
23/05/25	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences	AQ
09/05/25	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights	AQ
03/03/25	PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights	AQ
11/02/25	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences	AQ
07/11/24	PMV Pharmaceuticals : Reports Third Quarter 2024 Financial Results Form 8 K	PU
07/11/24	PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results	AQ
23/10/24	PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial	AQ
08/08/24	PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial	AQ
30/05/24	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	AQ
29/05/24	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	AQ